drugset / Trial / NCT06430866
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to demonstrate pharmacokinetic (PK) similarity ABP 234 with pembrolizumab.
Timeline
- Start
- 2024-09-12
- Primary completion
- 2026-12-14
- Completion
- 2026-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABP 234 | Unknown | — | Intravenous |
| Comparator | Pembrolizumab | Monoclonal antibody | — | Intravenous |